Carbon dioxide 5% / Oxygen 95%
Available from a pharmacy with pharmacist advice
Carbon dioxide is a colorless, odorless gas vital to life on Earth.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Oxygen + Carbon dioxide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
9 branded products available
MHRA licensed products
View all licensed products for Oxygen + Carbon dioxide on the MHRA register
Carbon dioxide 5% / Oxygen 95% cylinders size F
Carbon dioxide 5% / Oxygen 95% cylinders size G
Carbon dioxide 5% / Oxygen 95% cylinders size J
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(15)
Extracorporeal carbon dioxide removal for acute respiratory failure (HTG703)
Specialist neonatal respiratory care for babies born preterm (NG124)
OxyMask for delivering oxygen therapy (MIB160)
Chronic obstructive pulmonary disease in adults (QS10)
Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s (NG202)
Extracorporeal membrane oxygenation for severe acute respiratory failure in adults (HTG260)
Lung volume reduction surgery for advanced emphysema (HTG69)
COVID-19 rapid guideline: managing COVID-19 (NG191)
Extracorporeal membrane oxygenation (ECMO) in postneonatal children (HTG17)
i STAT CG4+ and CHEM8+ cartridges for point-of-care testing in the emergency department (MIB38)
Thoracoscopic repair of congenital diaphragmatic hernia in neonates (HTG247)
End-tidal Control software for use with Aisys closed circuit anaesthesia systems for automated gas control during general anaesthesia (MIB10)
VA ECMO for postcardiotomy cardiogenic shock in adults (HTG762)
VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest (HTG765)
ERBE flexible cryoprobes for bronchoscopic diagnosis and treatment (MIB39)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 6 · 1945–2026
Showing the 50 most relevant studies, sorted by most relevant.
Cheonghee Kim, F. Dionigi, V. Beermann, et al.
Advanced Materials, 2018
P. D. Dissanayake, Siming You, A. Igalavithana, et al.
Renewable and Sustainable Energy Reviews, 2020
Abstract Carbon dioxide (CO2) is the main anthropogenic greenhouse gas contributing to global warming, causing tremendous impacts on the global ecosystem. Fossil fuel combustion is the main anthropogenic source of CO2 emissions. Biochar, a porous carbonaceous material produced through the thermochemical conversion of organic materials in oxygen-depleted conditions, is emerging as a cost-effective green sorbent to maintain environmental quality by capturing CO2. Currently, the modification of biochar using different physico-chemical processes, as well as the synthesis of biochar composites to enhance the contaminant sorption capacity, has drawn significant interest from the scientific community, which could also be used for capturing CO2. This review summarizes and evaluates the potential of using pristine and engineered biochar as CO2 capturing media, as well as the factors influencing the CO2 adsorption capacity of biochar and issues related to the synthesis of biochar-based CO2 adsorbents. The CO2 adsorption capacity of biochar is greatly governed by physico-chemical properties of biochar such as specific surface area, microporosity, aromaticity, hydrophobicity and the presence of basic functional groups which are influenced by feedstock type and production conditions of biochar. Micropore area (R2 = 0.9032, n = 32) and micropore volume (R2 = 0.8793, n = 32) showed a significant positive relationship with CO2 adsorption capacity of biochar. These properties of biochar are closely related to the type of feedstock and the thermochemical conditions of biochar production. Engineered biochar significantly increases CO2 adsorption capacity of pristine biochar due to modification of surface properties. Despite the progress in biochar development, further studies should be conducted to develop cost-effective, sustainable biochar-based composites for use in large-scale CO2 capture.
Abstract licence: CC BY-SA
X. Su, Jinghua Xu, Binglian Liang, et al.
Journal of Energy Chemistry, 2016
Marktus A. Atanga, F. Rezaei, A. Jawad, et al.
Applied Catalysis B-environmental, 2018
J. Kasting
Precambrian research, 1987
Zuozhong Liang, Hong-Yan Wang, Haoquan Zheng, et al.
Chemical Society reviews, 2021
Shan Gao, Zhongti Sun, Wei Liu, et al.
Nature Communications, 2017
Dunfeng Gao, I. Zegkinoglou, N. J. Divins, et al.
ACS nano, 2017
A. Eilert, F. Cavalca, F. Roberts, et al.
The journal of physical chemistry letters, 2017
Lei Wang, Liang Chen, Daniel C W Tsang, et al.
Journal of Cleaner Production, 2020
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
Not available
Mechanism
Data not found.
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
Protein binding
Volume of distribution
Metabolism
Elimination
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
ATC V03AN02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72